The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed
dramatically in the past 15 years. This has been due to the development of tyrosine kinase …

Treatments for chronic myeloid leukemia (CML) represent a success story in molecular
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …

The introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), has
revolutionized the treatment of chronic myeloid leukemia (CML). By directly targeting the Bcr …

Identification of BCR‐ABL as the defining leukemogenic event in chronic myelogenous
leukemia (CML) revolutionized the treatment of the disease. Imatinib, a potent BCR‐ABL …

The treatment of chronic myelogenous leukemia (CML) has been revolutionized by the
development of the small-molecule tyrosine kinase inhibitor imatinib. The primary target for …

Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management
of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60 …

Imatinib is considered standard therapy for patients with chronic myelogenous leukemia
(CML), inducing a high rate of hematologic and cytogenetic responses. Despite these …

Abstract Development of the highly selective targeted tyrosine kinase inhibitors (TKIs) has
expanded the therapeutic options for chronic myeloid leukemia (CML). Patients undergoing …

Purpose of Review A large number of chronic myeloid leukemia (CML) patients receiving
tyrosine kinase inhibitors (TKIs) can now enjoy a deep molecular control of the disease and …

The biology of chronic myeloid leukemia (CML) has enabled pioneering studies with
targeted therapies. BCR-ABL inhibition with imatinib results in high levels of efficacy in …